GeneSystem Co

GeneSystem Co EBITDA Margin

The EBITDA Margin of GeneSystem Co (363250.KQ) as of Oct 29, 2026 is -2,540.06 %. In the previous year, EBITDA Margin was -746.80 % — a change of 240.12% (lower).

EBITDA Margin

-2,540.06 %

YoY

240.12%

Last updated:

EBITDA Margin of GeneSystem Co is 2025 -2,540.06 % . EBITDA Margin of GeneSystem Co was 2024 -746.80 % . It decreases by 240.12% lower compared to the previous year.

The GeneSystem Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
-324.33 KRW
Jan 1, 2019
-211.45 KRW
Jan 1, 2020
26.07 KRW
Jan 1, 2021
18.65 KRW
Jan 1, 2022
-173.59 KRW
Jan 1, 2023
-1,011.48 KRW
Jan 1, 2024
-746.80 KRW
Jan 1, 2025
-2,540.06 KRW
The GeneSystem Co EBITDA Margin history
YEAREBITDA MarginYoY
-2,540.06 %+240.12%
-746.80 %-26.17%
-1,011.48 %+482.69%
-173.59 %-1,030.57%
18.65 %-28.44%
26.07 %-112.33%
-211.45 %-34.80%
-324.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

GeneSystem Co Stock analysis

What does GeneSystem Co do? GeneSystem Co., Ltd generates revenue through the development, manufacturing, and sale of PCR-based molecular diagnostic products. The company offers molecular diagnosis systems, biochips, test kits, and reaction reagents, targeting healthcare providers and laboratories seeking advanced in vitro diagnostic solutions. Its core business focuses on molecular diagnosis technology, complementing immunodiagnosis technology to deliver comprehensive diagnostic tools. The firm serves medical institutions requiring precise and efficient diagnostic equipment for disease detection and monitoring. The company's product portfolio includes platform-based molecular diagnostic systems, biochips, and test kits designed for laboratory use. These products are sold directly to healthcare facilities and diagnostic laboratories, supporting applications in infectious disease testing and genetic analysis. By leveraging its expertise in molecular diagnosis, GeneSystem Co., Ltd provides essential tools for medical professionals to enhance diagnostic accuracy and patient care. GeneSystem Co., Ltd's revenue streams are derived from the sale of diagnostic systems, biochips, and consumables such as test kits and reaction reagents. The firm's target market comprises healthcare institutions and laboratories that require reliable in vitro diagnostic technology. The company's focus on molecular diagnosis technology positions it as a key supplier in the diagnostic equipment sector, meeting the growing demand for advanced diagnostic solutions in healthcare. GeneSystem Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GeneSystem Co stock

EBITDA Margin of GeneSystem Co is -2,540.06 % in 2025.

EBITDA Margin of GeneSystem Co changed from -746.80 % to -2,540.06 %, representing a 240.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin GeneSystem Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's GeneSystem Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — GeneSystem Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — GeneSystem Co